A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation

Abstract Background Microwave ablation (MWA) has become an alternative treatment for unresectable hepatocellular carcinoma (HCC), but it does not eliminate the risk of recurrence and metastasis after treatment. Recent studies have demonstrated that miR-34a presents decreased gene expression in resid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jian Hu, Wenceng Pei, Zhenyou Jiang, Zihuang Li
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Hepatocellular carcinoma Microwave ablation Nanodrug delivery Arsenic trioxide miR-34a Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/bafcb8d8b86144d0b2b9ff6eb7fb6a84
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bafcb8d8b86144d0b2b9ff6eb7fb6a84
record_format	dspace
spelling	oai:doaj.org-article:bafcb8d8b86144d0b2b9ff6eb7fb6a842021-11-28T12:09:50ZA combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation10.1186/s12645-021-00105-81868-69581868-6966https://doaj.org/article/bafcb8d8b86144d0b2b9ff6eb7fb6a842021-11-01T00:00:00Zhttps://doi.org/10.1186/s12645-021-00105-8https://doaj.org/toc/1868-6958https://doaj.org/toc/1868-6966Abstract Background Microwave ablation (MWA) has become an alternative treatment for unresectable hepatocellular carcinoma (HCC), but it does not eliminate the risk of recurrence and metastasis after treatment. Recent studies have demonstrated that miR-34a presents decreased gene expression in residual tumours after ablation therapy and can increase the therapeutic effect of arsenic trioxide against HCC, which brings new opportunities for HCC treatment. Methods A pH-sensitive charge inversion material was used to construct a nanotargeted delivery system based on the synergistic effects of miR-34a and As2O3. We established in vitro and in vivo models of HCC microwave ablation and performed in-depth research on the dual-drug system to inhibit the rapid progression and induce pyroptosis in HCC cells after microwave ablation. Results The antitumour effects were enhanced with the dual-drug nanoparticles relative to the single-drug formulations, and the therapeutic efficacy of the nanoparticles was more significant in a weakly acidic environment. The dual-drug nanoparticles increased the N-terminal portion of GSDME and decreased the expression of Cyt-c and c-met. Conclusions Dual-drug nanoparticles may improve the therapeutic efficacy of HCC treatment after insufficient ablation through Cyt-c and GSDME-N and decrease the expression levels of c-met. These nanoparticles are expected to provide new treatment methods for residual HCC after MWA, prolong the survival of patients and improve their quality of life.Jian HuWenceng PeiZhenyou JiangZihuang LiBMCarticleHepatocellular carcinomaMicrowave ablationNanodrug deliveryArsenic trioxidemiR-34aNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Nanotechnology, Vol 12, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Hepatocellular carcinoma Microwave ablation Nanodrug delivery Arsenic trioxide miR-34a Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Hepatocellular carcinoma Microwave ablation Nanodrug delivery Arsenic trioxide miR-34a Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jian Hu Wenceng Pei Zhenyou Jiang Zihuang Li A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation
description	Abstract Background Microwave ablation (MWA) has become an alternative treatment for unresectable hepatocellular carcinoma (HCC), but it does not eliminate the risk of recurrence and metastasis after treatment. Recent studies have demonstrated that miR-34a presents decreased gene expression in residual tumours after ablation therapy and can increase the therapeutic effect of arsenic trioxide against HCC, which brings new opportunities for HCC treatment. Methods A pH-sensitive charge inversion material was used to construct a nanotargeted delivery system based on the synergistic effects of miR-34a and As2O3. We established in vitro and in vivo models of HCC microwave ablation and performed in-depth research on the dual-drug system to inhibit the rapid progression and induce pyroptosis in HCC cells after microwave ablation. Results The antitumour effects were enhanced with the dual-drug nanoparticles relative to the single-drug formulations, and the therapeutic efficacy of the nanoparticles was more significant in a weakly acidic environment. The dual-drug nanoparticles increased the N-terminal portion of GSDME and decreased the expression of Cyt-c and c-met. Conclusions Dual-drug nanoparticles may improve the therapeutic efficacy of HCC treatment after insufficient ablation through Cyt-c and GSDME-N and decrease the expression levels of c-met. These nanoparticles are expected to provide new treatment methods for residual HCC after MWA, prolong the survival of patients and improve their quality of life.
format	article
author	Jian Hu Wenceng Pei Zhenyou Jiang Zihuang Li
author_facet	Jian Hu Wenceng Pei Zhenyou Jiang Zihuang Li
author_sort	Jian Hu
title	A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation
title_short	A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation
title_full	A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation
title_fullStr	A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation
title_full_unstemmed	A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation
title_sort	combined mir-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of hcc progression after microwave ablation
publisher	BMC
publishDate	2021
url	https://doaj.org/article/bafcb8d8b86144d0b2b9ff6eb7fb6a84
work_keys_str_mv	AT jianhu acombinedmir34aandarsenictrioxidenanodrugdeliverysystemforsynergisticinhibitionofhccprogressionaftermicrowaveablation AT wencengpei acombinedmir34aandarsenictrioxidenanodrugdeliverysystemforsynergisticinhibitionofhccprogressionaftermicrowaveablation AT zhenyoujiang acombinedmir34aandarsenictrioxidenanodrugdeliverysystemforsynergisticinhibitionofhccprogressionaftermicrowaveablation AT zihuangli acombinedmir34aandarsenictrioxidenanodrugdeliverysystemforsynergisticinhibitionofhccprogressionaftermicrowaveablation AT jianhu combinedmir34aandarsenictrioxidenanodrugdeliverysystemforsynergisticinhibitionofhccprogressionaftermicrowaveablation AT wencengpei combinedmir34aandarsenictrioxidenanodrugdeliverysystemforsynergisticinhibitionofhccprogressionaftermicrowaveablation AT zhenyoujiang combinedmir34aandarsenictrioxidenanodrugdeliverysystemforsynergisticinhibitionofhccprogressionaftermicrowaveablation AT zihuangli combinedmir34aandarsenictrioxidenanodrugdeliverysystemforsynergisticinhibitionofhccprogressionaftermicrowaveablation
_version_	1718408163973136384

A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation

Ejemplares similares